News and Press Releases
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning
FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials 5 June 2024 -- Pennsylvania, US -- CluePoints, providers...
Category: Biotechnology, Pharmaceutical
Posted: June 5, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team
3 June 2024 -- Hampshire, UK -- TMC Pharma Services, an established global product development and clinical research organisation (CRO) headquartered in Hampshire, UK, is pleased to announce the appointment...
Category: Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
Michael McSorley appointed as new managing director of Origin
3 June 2024 -- Melton, UK -- Global pharmaceutical solutions provider, Origin, has today appointed Michael McSorley as new managing director. Michael McSorley With almost a decade’s experience in the...
Category: Logistics, Manufacturing and Packing
Posted: June 3, 2024
Ardena appoints Jeremie Trochu as Chief Executive Officer
3 June 2024 -- Ghent, Belgium -- Ardena today announces the retirement of Harry Christiaens PhD, and the subsequent appointment of Jeremie Trochu as chief executive officer. Jeremie is a...
Category: BioManufacturing, Biotechnology, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting
2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 2, 2024
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...
Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...
Category: Biotechnology, Clinical Trials
Posted: May 22, 2024
Generis Welcomes Max Kelleher as New Chief Executive Officer
14 May 2024 -- London, UK -- Generis, creator of the cloud data, content and business process management platform CARA, today announced that Max Kelleher will be stepping into the...
Category: Biotechnology, Other
Posted: May 14, 2024
ERS Genomics appoints John E Milad as Chief Executive Officer
13 May 2024 -- Dublin, Ireland -- ERS Genomics, the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25...
Category: Drug Delivery, Drug Discovery
Posted: May 13, 2024
Verisense Health Elects Josh Tolkoff to its Board of Directors
Josh brings extensive medical device, investment and growth management experience to his new role 9 May 2024 -- Massachusetts, US -- Verisense Health, a digital health technology and data company,...
Category: Biotechnology, Other
Posted: May 9, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
